Skip to main content

Table 2 IOP (mm Hg) in both groups

From: Efficacy of intravitreal ranibizumab combined with Ahmed glaucoma valve implantation for the treatment of neovascular glaucoma

 

Pre-surgery

2 weeks

1 month

3 months

6 months

12 months

Injection Group IOP (mean ± SD)

46.4 ± 13.3

14.5 ± 4.4

16.9 ± 4.2

18.1 ± 3.8

20.5 ± 4.5

21.1 ± 4.2

(Minimum - Maximum)

(24.5–76.0)

(6.5–24.0)

(9.0–26.0)

(10.0–24.0)

(14.0–28.0)

(15.5–28.0)

Control Group IOP (mean ± SD)

45.0 ± 14.9

15.6 ± 5.6

17.1 ± 5.3

19.4 ± 5.0

20.2 ± 3.9

22.1 ± 4.7

(Minimum - Maximum)

(23.5–78.5)

(6.0–27.5)

(8.0–28.0)

(12.0–31.5)

(14.5–27.0)

(12.0–30.0)

P

0.74

0.51

0.85

0.35

0.83

0.53

  1. Note: IOPs before surgery and at two weeks, one month, three months, six months and 12 months after surgery were determined using an applanation tonometer (mean of 9 am and 4 pm measurements). Differences in IOPs at various time points throughout follow-up were compared between the two groups using the t test